Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Bego�a Benito VillabrigaDANAMI-2 TrialDANAMI-2 Trial
Bego�a Benito VillabrigaDANAMI-2 Trial
Background
Bego�a Benito VillabrigaDANAMI-2 Trial
Objective
Bego�a Benito VillabrigaDANAMI-2 Trial
Study design
Bego�a Benito VillabrigaDANAMI-2 Trial
Study design
Bego�a Benito VillabrigaDANAMI-2 Trial
Study end-points
High data completeness:
- Vital status: 99.7%
- - cause of deaths ...
Bego�a Benito VillabrigaDANAMI-2 Trial
Results: Baseline characteristics
Bego�a Benito VillabrigaDANAMI-2 Trial
Results: Time to treatment
Bego�a Benito VillabrigaDANAMI-2 Trial
Results: Primary end-point (16y FUP)
Death or re-MI
Bego�a Benito VillabrigaDANAMI-2 Trial
22.7%
18.3%
Cardiac death
Results: secondary end-points (16y FUP)
24.5%
19.0%
re-MI...
Bego�a Benito VillabrigaDANAMI-2 Trial
Subgroup of Referral Hospitals
Favours pPCI Favours fibrinolysis
Bego�a Benito VillabrigaDANAMI-2 Trial
Limitations
Bego�a Benito VillabrigaDANAMI-2 Trial
Conclusions
In patients with STEMI randomized to fibrinolysis vs pPCI, at 16-year f...
Bego�a Benito VillabrigaDANAMI-2 Trial
Upcoming SlideShare
Loading in …5
×

DANAMI 2 Trial

31 views

Published on

La Dra. Begoña Benito Villabriga sintetiza los resultados de la actualización del estudio sobre infarto agudo de miocardio.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

DANAMI 2 Trial

  1. 1. Bego�a Benito VillabrigaDANAMI-2 TrialDANAMI-2 Trial
  2. 2. Bego�a Benito VillabrigaDANAMI-2 Trial Background
  3. 3. Bego�a Benito VillabrigaDANAMI-2 Trial Objective
  4. 4. Bego�a Benito VillabrigaDANAMI-2 Trial Study design
  5. 5. Bego�a Benito VillabrigaDANAMI-2 Trial Study design
  6. 6. Bego�a Benito VillabrigaDANAMI-2 Trial Study end-points High data completeness: - Vital status: 99.7% - - cause of deaths 97.7%
  7. 7. Bego�a Benito VillabrigaDANAMI-2 Trial Results: Baseline characteristics
  8. 8. Bego�a Benito VillabrigaDANAMI-2 Trial Results: Time to treatment
  9. 9. Bego�a Benito VillabrigaDANAMI-2 Trial Results: Primary end-point (16y FUP) Death or re-MI
  10. 10. Bego�a Benito VillabrigaDANAMI-2 Trial 22.7% 18.3% Cardiac death Results: secondary end-points (16y FUP) 24.5% 19.0% re-MI 51.3% 50.5% All-cause death
  11. 11. Bego�a Benito VillabrigaDANAMI-2 Trial Subgroup of Referral Hospitals Favours pPCI Favours fibrinolysis
  12. 12. Bego�a Benito VillabrigaDANAMI-2 Trial Limitations
  13. 13. Bego�a Benito VillabrigaDANAMI-2 Trial Conclusions In patients with STEMI randomized to fibrinolysis vs pPCI, at 16-year follow-up: (Death or re-MI)
  14. 14. Bego�a Benito VillabrigaDANAMI-2 Trial

×